Predictive Oncology (NASDAQ:POAI) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

Predictive Oncology Inc. (NASDAQ:POAI) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $13.82 and traded as low as $9.26. Predictive Oncology shares last traded at $9.42, with a volume of 22,443 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Predictive Oncology in a research report on Wednesday, October 8th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Predictive Oncology currently has an average rating of “Reduce”.

Predictive Oncology Stock Performance

The stock has a fifty day moving average price of $13.85 and a 200-day moving average price of $13.82. The firm has a market capitalization of $7.19 million, a PE ratio of -3.09 and a beta of 1.32.

Predictive Oncology (NASDAQ:POAI) last announced its quarterly earnings results on Wednesday, August 13th. The medical instruments supplier reported ($3.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($1.95). Predictive Oncology had a negative net margin of 587.31% and a negative return on equity of 722.01%. The company had revenue of $0.00 million during the quarter, compared to analysts’ expectations of $1.50 million. Research analysts expect that Predictive Oncology Inc. will post -2.08 earnings per share for the current fiscal year.

Predictive Oncology Company Profile

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.